These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 26049551)

  • 21. Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
    Powell DR; Zambrowicz B; Morrow L; Beysen C; Hompesch M; Turner S; Hellerstein M; Banks P; Strumph P; Lapuerta P
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1235-49. PubMed ID: 31837264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
    Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Carroll AK; Lapuerta P; Banks P; Agarwal R
    Diabetes Obes Metab; 2021 Dec; 23(12):2632-2642. PubMed ID: 34338408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
    Bode BW; Cengiz E; Wadwa RP; Banks P; Danne T; Kushner JA; McGuire DK; Peters AL; Strumph P; Sawhney S
    Diabetes Technol Ther; 2021 Jan; 23(1):59-69. PubMed ID: 32640846
    [No Abstract]   [Full Text] [Related]  

  • 24. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
    Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
    Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
    Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
    Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
    [No Abstract]   [Full Text] [Related]  

  • 26. Sotagliflozin: A Review in Type 1 Diabetes.
    Deeks ED
    Drugs; 2019 Dec; 79(18):1977-1987. PubMed ID: 31761990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
    Kim YJ; Hwang SD; Lim S
    Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
    Sims H; Smith KH; Bramlage P; Minguet J
    Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
    Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
    Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin.
    Boeder S; Davies MJ; McGill JB; Pratley R; Girard M; Banks P; Pettus J; Garg S
    Diabetes Technol Ther; 2024 Sep; 26(9):618-625. PubMed ID: 38441906
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.
    Biester T; Aschemeier B; Fath M; Frey M; Scheerer MF; Kordonouri O; Danne T
    Diabetes Obes Metab; 2017 Nov; 19(11):1635-1639. PubMed ID: 28417527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
    Lapuerta P; Zambrowicz B; Strumph P; Sands A
    Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
    Peters AL; McGuire DK; Danne T; Kushner JA; Rodbard HW; Dhatariya K; Sawhney S; Banks P; Jiang W; Davies MJ; Lapuerta P
    Diabetes Care; 2020 Nov; 43(11):2713-2720. PubMed ID: 32928957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.
    Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E;
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
    Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
    Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
    Rodbard HW; Giaccari A; Cariou B; Garg S; Davies MJ; Seth K; Sawhney S
    Diab Vasc Dis Res; 2021; 18(1):1479164121995928. PubMed ID: 33611925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of sotagliflozin in treating diabetes type 1.
    Rendell MS
    Expert Opin Pharmacother; 2018 Feb; 19(3):307-315. PubMed ID: 29212386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
    Cariou B; Charbonnel B
    Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.